LI
CUE icon

Leap Investments’s Cue Biopharma CUE Stock Holding History

Leap Investments’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$304K Buy
+413
New +$299K 0.2% 204
2020
Q1 		– Sell
-506
Closed -$241K – 398
2019
Q4 		$241K Buy
+506
New +$159K 0.11% 286

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Leap Investments's CUE Position: Q2 2020 in Review

Leap Investments opened a new position in Cue Biopharma (CUE) in Q2 2020: 413 shares worth $304K. The stake represents 0.2% of the portfolio and ranks #204 among its holdings. This is a return to the name: Leap Investments previously reported a position in CUE as recently as Q4 2019.

Leap Investments first reported a position in CUE in Q4 2019 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold CUE as of Q2 2020.

  • Leap Investments held 413 shares of Cue Biopharma worth $304K as of Q2 2020.
  • Cue Biopharma was a new Leap Investments position in Q2 2020.
  • Cue Biopharma made up 0.2% of Leap Investments's portfolio in Q2 2020, its #204 holding.
  • Leap Investments first reported a position in Cue Biopharma in Q4 2019 and has held it in 2 quarters since.
  • 99 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.